研究单位：[1]Ruijin Hospital[2]Cancer Hospital Chinese Academy of Medical Sciences Beijing, China[3]Xiangya Hospital Central South University Changsha, China[4]Heping Hospital Affiliated to Changzhi Medical College Changzhi, China[5]Sichuan Cancer Hospital & Institute Chengdu, China[6]Sichuan Provincial People's Hospital Chengdu, China[7]The Affiliated Hospital of Guizhou Medical University Guiyang, China[8]Hainan Cancer Hospital Haikou, China[9]Cancer Hospital of the University of Chinese Academy of Sciences Hangzhou, China[10]The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, China[11]Hefei Cancer Hospital, Chinese Academy of Sciences Hefei, China[12]Lanzhou University Second Hospital Lanzhou, China[13]Changhai Hospital Shanghai, China[14]Ruijin Hospital, Shanghai Jiaotong University School of Medicine Shanghai, China[15]Liaoning Cancer Hospita & Institute Shenyang, China[16]The Fourth Hospital of Hebei Medical University Shijiazhuang, China河北医科大学第四医院[17]Jilin Guowen Hospital Siping, China[18]Shanxi Provincial Cancer Hospital Taiyuan, China[19]First Affiliated Hospital of Xi'an Jiaotong University Xian, China[20]Tangdu Hospital Xian, China[21]Yantai Yuhuangding Hospital Yantai, China[22]Henan Provincial Cancer Hospital Zhengzhou, China[23]Affiliated Hospital of Jiangsu University Zhenjiang, China[24]Affiliated Hospital of Hebei University Baoding, China
研究目的：
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
